PEAK-1 Study – Clear cell Renal Cell Carcinoma
Study Background
This clinical trial is investigating an experimental study drug (casdatifan) for people living with unresectable, locally advanced, or metastatic renal cell carcinoma with a primary clear cell component. The purpose of the study is to determine if the study drug improves patient outcomes compared to standard treatment.
Eligibility Criteria
Clinical trials have complex eligibility criteria. We encourage you to speak to your primary doctor or medical oncologist if you are unsure.
Alternatively, if you wish to chat to our oncology nursing team, you can contact us directly at – cancertrials@canopyclinical.com.au
Please note if you are referring a patient, you can use the referral form attached.
Inclusion (Minimum requirements)
- Aged 18 years and above
- Unresectable (cannot be surgically removed or fully removed/resected), locally advanced or metastatic renal cell carcinoma with a primary clear cell component.
- You have had previous immunotherapy treatment (anti-PD-1 or anti-PD-L) but your cancer has progressed or has not responded to the treatment
Exclusion (Generally not allowed)
- Received prior treatment with a HIF-2α inhibitor or cabozantinib.
- Have had another active cancer within the previous year except for locally curable cancers that have been apparently cured.
- Uncontrolled or poorly controlled hypertension, as defined by a sustained blood pressure > 140/90 mm Hg on more than three antihypertensives
Please note this is not a complete list of inclusion and exclusion criteria. If you appear suitable based on the above criteria, the next step will be a pre-screening call with our oncology nursing team.
More information: NCT07011719









